Peter Keeling
Founder | Precision Medicine Commercialization
Peter Keeling founded Diaceutics in 2005 and has grown it into a global leader in precision medicine commercialization, supporting many of the world's most important biomarker and diagnostic strategies. With more than 33 years of experience as a pharma executive, entrepreneur and strategist, he has been at the forefront of transforming how precision medicine is brought to market, pioneering innovative commercial models across therapeutics, diagnostics and FMCG.
A recognised thought leader and published author, Peter is a sought-after speaker on the future of precision medicine and healthcare innovation. He holds degrees from Queen's University Belfast and Buckingham University and was a Visiting Fellow at MIT's Sloan School of Management.
Connect
Peter Keeling founded Diaceutics in 2005 and has grown it into a global leader in precision medicine commercialization, supporting many of the world's most important biomarker and diagnostic strategies. With more than 33 years of experience as a pharma executive, entrepreneur and strategist, he has been at the forefront of transforming how precision medicine is brought to market, pioneering innovative commercial models across therapeutics, diagnostics and FMCG.
A recognised thought leader and published author, Peter is a sought-after speaker on the future of precision medicine and healthcare innovation. He holds degrees from Queen's University Belfast and Buckingham University and was a Visiting Fellow at MIT's Sloan School of Management.
Resources written by Peter Keeling :
Identifying Barriers to Biomarker Testing Efficiency: 100 Laboratories Mapped in 3 Months
Diaceutics enhances biomarker testing efficiency, engaging over 150 labs to identify workflow barriers, optimize practices, and support timely clinical decision-making for better patient outcomes.